InflaRx N.V. IFRX

Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows: Cantor Global Healthcare Conference 2026September 9 - 11, 2026 in New York, NYFireside chat on September 9th at 3:20 PM ET InflaRx will also conduct one-on-one investor meetings on September 9th. A link to vie

Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aRPharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflamma

Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. No conference call is planned. About InflaRx N.V. InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprieta

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient development plan to bring the C5a/C5aR inhibition mechanism to patientsPreviously announced Phase 2 planning with izicopan in AAV continues uninterrupted Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics

While InflaRx N.V. (NASDAQ:IFRX) has gained 82.18% year-to-date, analysts continue to see 385.90% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. That analyst conviction only strengthened by mid-May, with two firm upgrades and target raises arriving back-to-back following a corporate update and first-quarter results. On May […]

InflaRx N.V. (NASDAQ:IFRX) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Raymond James said sentiment is increasingly supported by a constructive view of InflaRx’s izicopan program in […]

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses. The Company i

InflaRx N.V. (NASDAQ:IFRX) is one of the top 10 hot penny stocks to buy now. InflaRx N.V. (NASDAQ:IFRX) announced on April 28 that it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 27, informing management that the company regained compliance with Nasdaq’s minimum bid price requirement […]

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of cust

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseasesCapital Markets Day highlighting the promise and potential of izicopan in AAV and broader renal disorders now planned for summer 2026The Company estimates it will have sufficient funds for currently planned clinical development activities and ongoing operations through 2029InflaRx will continue to engage in dialog with

JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new pre-clinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reactive metabolite formation is widely used in drug development as an early mechanistic indicator of potential bioactivation-related safety risk. Izicopan is an investigational next-generatio

JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the first quarter 2026 on May 7, 2026, before the market opens. No conference call is planned. About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary